Study of Low-dose Naltrexone in Chronic Migraine With Fibromyalgia
Prospective Observational Pilot Study of Low-dose Naltrexone in Patients With Chronic Migraine With Comorbid Fibromyalgia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Jefferson Headache Center
-
Contact:
- Michael Marmura, MD
- Phone Number: 215-955-2243
- Email: michael.marmura@jefferson.edu
-
Sub-Investigator:
- Joshua B Katz, BA
-
Sub-Investigator:
- Nathalia Figueiredo, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects will be adults of all genders ages 18 and older.
- Patients with a diagnosis of CM (with or without NDPH) by IHC-3 criteria, diagnosed by a certified headache specialist.
- Subjects who received a new prescription for LDN
- Fibromyalgia-diagnosed according to Fibromyalgia Rapid Screening Tool
- Subjects should be on stable headache and migraine preventives for the past 2 months with no plans to change medication for the next 4 months.
- Subjects willing to maintain a headache/migraine diary one month prior to taking medication and while taking the medication, either physical or electronic diary of their choice.
- Subjects willing to fill out pre and post intervention surveys
- Subjects willing to comply with planned follow up phone calls and visits.
Exclusion Criteria:
- Not planning on follow up care with clinician.
- Patients with decreased decision-making capacity in which the investigator's opinion would interfere with the person's ability to provide informed consent and complete study questionnaires.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effectiveness on migraine
Time Frame: 9-12 weeks
|
Monthly migraine days
|
9-12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effectiveness on headache
Time Frame: 9-12 weeks
|
Monthly headache days
|
9-12 weeks
|
|
Intensity
Time Frame: 9-12 weeks
|
Average peak intensity of migraine
|
9-12 weeks
|
|
The Migraine Disability Assessment Test
Time Frame: 9-12 weeks
|
Impact of migraine on daily life
|
9-12 weeks
|
|
Migraine Specific Quality of Life Index
Time Frame: 9-12 weeks
|
Impact of migraine and migraine treatment on quality of life
|
9-12 weeks
|
|
Patient Health Questionnaire
Time Frame: 9-12 weeks
|
Monitor depression and changes in signs/symptoms of depression
|
9-12 weeks
|
|
Fibromyalgia Impact Questionnaire
Time Frame: 9-12 weeks
|
Assess health status of patients with fibromyalgia
|
9-12 weeks
|
|
Patients' Global Impression of Change
Time Frame: 9-12 weeks
|
Assess patient's belief in efficacy of treatment
|
9-12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Musculoskeletal Diseases
- Rheumatic Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Headache Disorders, Primary
- Headache Disorders
- Fibromyalgia
- Myofascial Pain Syndromes
- Migraine Disorders
- Headache
Other Study ID Numbers
Other Study ID Numbers
- 22D.486
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.